UnitedHealth Group Inc. (NYSE:UNH)

The financial ratios presented demonstrate several notable trends between 2021 and 2025. Generally, adjusted ratios exhibit less volatility than their reported counterparts, suggesting the adjustments mitigate the impact of certain accounting treatments. Asset turnover, both reported and adjusted, shows a slight increasing trend over the period, culminating in a higher value in 2025 compared to 2021. Liquidity, as measured by the current ratio, remains relatively stable, with a minor increase in 2024 before returning to levels similar to those observed in 2021 and 2022. Leverage ratios indicate a gradual increase in debt relative to equity and capital over the five-year period, though the adjusted figures consistently show lower leverage than those reported. Profitability metrics, specifically net profit margin, demonstrate a significant decline from 2023 to 2025, while return on equity and return on assets also exhibit downward trends, particularly in the later years of the period.

Asset Turnover

Both reported and adjusted total asset turnover ratios remain relatively consistent, fluctuating between 1.30 and 1.43. A slight upward trend is evident, with 2025 showing the highest value in the observed period. The adjusted ratio consistently falls slightly below the reported ratio, indicating that the adjustments reduce the calculated turnover.

Liquidity

The reported current ratio exhibits minor fluctuations, remaining below 0.80 for most of the period, with a peak of 0.83 in 2024. The adjusted current ratio is consistently higher, ranging from 0.83 to 0.89, suggesting improved liquidity when adjustments are considered. The difference between reported and adjusted ratios indicates potential timing differences in recognizing current assets or liabilities.

Leverage

Debt to equity and debt to capital ratios both show an increasing trend from 2021 to 2025. The adjusted ratios are consistently lower than the reported ratios, implying that the adjustments reduce the calculated leverage. Financial leverage also increases over the period, though the adjusted figures are notably lower, indicating a more conservative leverage position when adjustments are applied.

Profitability

The reported net profit margin declines substantially from 6.06% in 2021 to 2.72% in 2025. The adjusted net profit margin mirrors this trend, though the magnitude of the decline is less pronounced. Return on equity and return on assets also demonstrate a significant downward trend, with both ratios decreasing substantially between 2021 and 2025. The adjusted ROE and ROA are consistently lower than the reported values, suggesting that the adjustments negatively impact profitability metrics.

In summary, while asset utilization remains stable and liquidity shows minor improvements, the observed increase in leverage coupled with the significant decline in profitability metrics warrants further investigation. The consistent differences between reported and adjusted ratios highlight the importance of understanding the nature of the adjustments and their impact on the overall financial picture.

The adjusted total asset turnover ratio for the period demonstrates a generally stable performance with a slight upward trend towards the end of the observed timeframe. Revenues and total assets both increased consistently year-over-year. However, the adjusted total asset turnover ratio itself exhibits relatively minor fluctuations before showing a more pronounced increase in the final year.

Adjusted Total Asset Turnover Trend

The adjusted total asset turnover ratio began at 1.33 in 2021, decreased slightly to 1.30 in 2022, and then remained relatively consistent at 1.33 in 2023. A further slight decrease to 1.31 was observed in 2024, followed by a notable increase to 1.41 in 2025. This suggests a growing efficiency in asset utilization in the most recent year.

Revenue and Asset Growth

Adjusted revenues increased from US$285,002 million in 2021 to US$443,743 million in 2025, representing a substantial overall growth. Adjusted total assets also increased, moving from US$214,153 million in 2021 to US$314,552 million in 2025. The consistent growth in both revenues and assets provides context for the observed turnover ratio trends.

Comparison to Reported Turnover

The reported total asset turnover ratio mirrors the adjusted ratio closely throughout the period. The difference between the reported and adjusted ratios is minimal in each year, indicating that the adjustments made do not significantly alter the overall assessment of asset utilization efficiency. Both reported and adjusted ratios show the same general trend of stability with a final year increase.

In summary, the adjusted total asset turnover ratio indicates a stable, and ultimately improving, ability to generate revenue from its asset base. The increase in the final year suggests enhanced operational efficiency or a shift in asset composition towards more productive assets.

The adjusted current ratio exhibited a generally positive trend over the five-year period, though with some fluctuation. While the reported current ratio remained relatively stable, the adjusted figures present a slightly different picture of the company’s short-term liquidity position.

Adjusted Current Ratio Trend

The adjusted current ratio began at 0.84 in 2021. It experienced a slight decrease to 0.83 in 2022 before increasing to 0.85 in 2023. A more pronounced increase was observed in 2024, reaching 0.89. The ratio then decreased slightly to 0.86 in 2025, but remained above the levels seen in 2021 and 2022.

Adjusted Assets and Liabilities

Adjusted current assets increased consistently from US$63,705 million in 2021 to US$95,553 million in 2025, indicating a general expansion of liquid assets. Adjusted current liabilities also increased over the same period, rising from US$75,721 million to US$111,484 million. However, the growth in adjusted assets generally outpaced the growth in adjusted liabilities, contributing to the observed improvement in the adjusted current ratio.

Comparison to Reported Current Ratio

The reported current ratio remained below 0.83 throughout the period, suggesting potential short-term liquidity concerns based on standard calculations. The adjusted current ratio, consistently higher than the reported ratio, indicates that the adjustments made to current assets and liabilities provide a more favorable view of the company’s ability to meet its short-term obligations. The difference between the reported and adjusted ratios suggests that certain current asset or liability classifications may be impacting the standard calculation.

Overall, the trend in the adjusted current ratio suggests improving short-term liquidity, despite increasing absolute levels of both current assets and current liabilities. The consistent difference between the reported and adjusted ratios warrants further investigation into the nature of the adjustments being made.

The adjusted debt to equity ratio exhibits an increasing trend over the five-year period. Total debt consistently increased from 2021 to 2025, while shareholders’ equity attributable to UnitedHealth Group also generally increased, though at a varying rate. The adjusted figures, incorporating modifications to both debt and equity, demonstrate a similar pattern, providing a refined view of the company’s financial leverage.

Adjusted Debt to Equity Ratio - Overall Trend

The adjusted debt to equity ratio rose from 0.60 in 2021 to 0.74 in 2025. This indicates a growing reliance on debt financing relative to equity financing over the observed period. The increase is not linear, with a more pronounced rise between 2021 and 2022, followed by a more moderate increase in subsequent years.

Debt and Equity Components

Adjusted total debt increased from US$50,276 million in 2021 to US$83,004 million in 2025, representing a 65.3% increase. Adjusted total equity also increased, moving from US$84,262 million in 2021 to US$112,503 million in 2025, a 33.5% increase. The faster growth of adjusted total debt compared to adjusted total equity is the primary driver of the increasing adjusted debt to equity ratio.

Year-over-Year Changes

The largest year-over-year increase in the adjusted debt to equity ratio occurred between 2021 and 2022, rising from 0.60 to 0.66. The increase from 2024 to 2025 was more modest, moving from 0.72 to 0.74. The rate of increase in the ratio slowed in the later years of the period.

Comparison to Reported Debt to Equity

The adjusted debt to equity ratio is consistently lower than the reported debt to equity ratio across all observed years. This suggests that the adjustments made to debt and equity result in a more conservative leverage profile. The reported ratio increased from 0.64 in 2021 to 0.83 in 2024 and remained at 0.83 in 2025, indicating a more substantial increase in leverage when using the reported figures.

In summary, the company experienced a consistent, though not always rapid, increase in its adjusted debt to equity ratio between 2021 and 2025. This trend is attributable to a faster rate of growth in adjusted total debt compared to adjusted total equity. The adjustments applied to the debt and equity figures appear to present a more conservative financial leverage position than the reported figures.

Over the five-year period ending December 31, 2025, both total debt and total capital exhibited an increasing trend. However, the adjusted figures present a slightly different picture, and the adjusted debt to capital ratio demonstrates a consistent pattern of fluctuation within a relatively narrow range. A detailed examination of these trends is presented below.

Total Debt and Total Capital

Total debt increased from US$46,003 million in 2021 to US$78,389 million in 2025, representing a substantial overall increase. Total capital also rose, moving from US$117,763 million in 2021 to US$172,499 million in 2025. The growth in capital generally kept pace with the growth in debt, as evidenced by the relatively stable reported debt to capital ratio.

Reported Debt to Capital Ratio

The reported debt to capital ratio began at 0.39 in 2021, increased to 0.43 in 2022, decreased slightly to 0.41 in 2023, and then rose again to 0.45 in both 2024 and 2025. This indicates a moderate increase in leverage over the period, with some year-to-year variability.

Adjusted Total Debt and Total Capital

Adjusted total debt increased from US$50,276 million in 2021 to US$83,004 million in 2025. Adjusted total capital also increased, moving from US$134,538 million in 2021 to US$195,507 million in 2025. The adjusted capital figure consistently exceeds the reported capital figure, and the adjusted debt figure exceeds the reported debt figure, suggesting the adjustments increase both values.

Adjusted Debt to Capital Ratio

The adjusted debt to capital ratio started at 0.37 in 2021, rose to 0.40 in 2022, decreased to 0.38 in 2023, and then increased to 0.42 in both 2024 and 2025. This trend mirrors the reported debt to capital ratio, although the specific values differ. The ratio remained relatively stable, fluctuating between 0.37 and 0.42 throughout the observed period. The consistency suggests a controlled approach to financial leverage, even after adjustments are considered.

In summary, while both debt and capital increased in absolute terms, the adjusted debt to capital ratio remained relatively consistent, indicating a stable capital structure over the five-year period. The adjustments to debt and capital consistently result in a slightly different ratio than the reported figures, but the overall trend remains similar.

An examination of the financial leverage metrics reveals trends in both reported and adjusted figures over the five-year period. Total assets exhibited a consistent upward trajectory, increasing from US$212,206 million in 2021 to US$309,581 million in 2025. Shareholders’ equity attributable to UnitedHealth Group also increased over the period, though at a slower rate, rising from US$71,760 million to US$94,110 million.

Reported Financial Leverage

Reported financial leverage demonstrated an increasing trend overall, beginning at 2.96 in 2021 and reaching 3.29 in 2025. While there was a slight increase from 2021 to 2022, and again from 2022 to 2024, the increase was more pronounced between 2024 and 2025. This suggests a growing reliance on debt financing relative to equity as reported.

Adjusted Total Assets and Equity

Adjusted total assets followed a similar upward trend to reported total assets, moving from US$214,153 million in 2021 to US$314,552 million in 2025. Adjusted total equity experienced a more substantial increase than reported equity, starting at US$84,262 million in 2021 and reaching US$112,503 million in 2025. This indicates that adjustments are increasing the equity base.

Adjusted Financial Leverage

Adjusted financial leverage showed a different pattern than the reported ratio. It began at 2.54 in 2021, increased to 2.62 in 2022, decreased slightly to 2.55 in 2023, and then increased to 2.80 in 2025. The adjustments consistently result in a lower leverage ratio compared to the reported figures. The increase from 2024 to 2025 is notable, mirroring the trend observed in the reported leverage, but remains below the reported leverage values. The adjustments appear to be mitigating the increase in leverage observed in the reported figures.

The divergence between reported and adjusted financial leverage suggests that the adjustments are related to items impacting equity. The consistent difference between the two metrics warrants further investigation to understand the nature of these adjustments and their impact on the overall financial risk profile.

The adjusted net profit margin exhibited fluctuating performance over the five-year period. Initial stability gave way to a significant increase, followed by a subsequent decline.

Overall Trend

From 2021 to 2023, the adjusted net profit margin increased from 5.59% to 6.88%. This positive trend reversed in 2024, with the margin decreasing to 4.89%, and continued to decline in 2025, reaching 3.06%.

Year-over-Year Changes

The period between 2021 and 2022 saw a slight decrease in the adjusted net profit margin, moving from 5.59% to 5.52%. The most substantial increase occurred between 2022 and 2023, with a rise of 1.36 percentage points. The largest decrease was observed between 2023 and 2024, a drop of 2.00 percentage points, and this downward trend accelerated between 2024 and 2025 with a decrease of 1.83 percentage points.

Relationship to Revenue

Adjusted revenues demonstrated consistent growth throughout the period, increasing from US$285,002 million in 2021 to US$443,743 million in 2025. However, the growth in adjusted net earnings did not consistently align with revenue growth. While adjusted net earnings increased alongside revenue from 2021 to 2023, they decreased in both 2024 and 2025, indicating that revenue growth did not translate into proportional profit gains during those years.

Comparison to Reported Margin

The adjusted net profit margin consistently differed from the reported net profit margin. The reported margin generally remained within a narrower range (between 3.65% and 6.25%) compared to the wider fluctuations observed in the adjusted margin. The difference between the adjusted and reported margins suggests the presence of significant adjustments impacting net earnings.

The declining adjusted net profit margin in the latter years, despite increasing revenues, warrants further investigation to identify the underlying factors contributing to this trend.

The adjusted return on equity (ROE) exhibited fluctuations over the five-year period. While net earnings attributable to UnitedHealth Group common shareholders and shareholders’ equity attributable to UnitedHealth Group both generally increased from 2021 to 2023, subsequent years showed declines in net earnings and continued growth in equity, impacting the ROE figures.

Adjusted ROE Trend

The adjusted ROE began at 18.91% in 2021, decreased slightly to 18.86% in 2022, then increased substantially to 23.36% in 2023. A decline was then observed in 2024, with the adjusted ROE falling to 17.03%, and continued downward in 2025 to 12.09%.

Relationship to Adjusted Net Earnings

Adjusted net earnings increased from US$15,931 million in 2021 to US$25,319 million in 2023, coinciding with the rise in adjusted ROE. However, adjusted net earnings decreased to US$19,313 million in 2024 and further to US$13,599 million in 2025, which correlates with the observed decline in adjusted ROE during those years.

Relationship to Adjusted Total Equity

Adjusted total equity consistently increased throughout the period, moving from US$84,262 million in 2021 to US$112,503 million in 2025. This consistent growth in the denominator of the ROE calculation likely contributed to the moderating effect on the ROE, particularly as adjusted net earnings began to decline in 2024 and 2025.

Comparison to Reported ROE

The reported ROE followed a similar pattern to the adjusted ROE, with a peak in 2022 at 25.87% and a subsequent decline to 12.81% in 2025. However, the reported ROE values were consistently higher than the adjusted ROE values across all years, indicating that adjustments to net earnings and total equity resulted in a lower ROE calculation.

The most significant change occurred between 2023 and 2025, where adjusted net earnings decreased by approximately 36.4% while adjusted total equity increased by approximately 6.4%. This combination resulted in a substantial decrease in the adjusted ROE from 23.36% to 12.09%.

The adjusted return on assets (ROA) exhibited fluctuating performance over the five-year period. While net earnings attributable to UnitedHealth Group common shareholders and total assets generally increased from 2021 to 2023, subsequent years showed declines in net earnings and continued asset growth. These movements significantly impacted the adjusted ROA.

Overall Trend

The adjusted ROA initially decreased from 7.44% in 2021 to 7.19% in 2022, before experiencing a substantial increase to 9.15% in 2023. This was followed by a decline to 6.39% in 2024 and a further decrease to 4.32% in 2025. This indicates a period of strong profitability in 2023, followed by diminishing returns.

Relationship to Net Earnings

The increase in adjusted ROA in 2023 aligns with a significant rise in adjusted net earnings, which grew from US$17,824 million in 2022 to US$25,319 million. Conversely, the declines in adjusted ROA in 2024 and 2025 correspond with decreases in adjusted net earnings to US$19,313 million and US$13,599 million, respectively. This suggests a strong correlation between profitability and the adjusted ROA.

Relationship to Total Assets

Adjusted total assets consistently increased throughout the period, moving from US$214,153 million in 2021 to US$314,552 million in 2025. The 2023 increase in adjusted ROA occurred despite asset growth, indicating improved efficiency in utilizing those assets. However, the subsequent declines in adjusted ROA, despite continued asset expansion, suggest that the company’s ability to generate earnings from its asset base diminished in the later years of the period.

Comparative Performance

The reported ROA generally mirrored the trend of the adjusted ROA, although the magnitudes of the changes differed. The adjusted ROA consistently remained below the reported ROA throughout the period, indicating that adjustments to net earnings and total assets resulted in a lower profitability metric. The largest difference between reported and adjusted ROA was observed in 2024 and 2025.

In summary, the adjusted ROA demonstrates a volatile pattern, heavily influenced by fluctuations in adjusted net earnings. While asset growth was consistent, the company’s efficiency in generating returns from those assets decreased in the final two years of the observed period.